New Delhi, Sept. 26 -- US President Donald Trump's latest tariff missile imposing a 100% levy on branded or patented pharmaceuticals is unlikely to have much impact on India's drug industry that mostly ships generic or off-patent medicines to the US, said industry experts.

However, at least one industry expert flagged a legal ambiguity related to generic drugs that are sold under brand names such as Crocin, saying these could face tariffs if treated as branded imports.

Two government officials said New Delhi is examining the impact of Trump's decision on India's generic drugs exported to the US.

"We [India's pharmaceutical industry] are largely into generic drug exports. Given their price competitiveness, we will continue to export to ...